Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 6/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406570 | 0.85 | ALDH1A1 (0.57) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL3403886 | 0.78 | CDC7 (0.43) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL3403482 | 0.77 | LMNA (0.62) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL404165 | 0.77 | ALDH1A1 (0.41) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL404166 | 0.77 | NPC1 (0.46) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL510314 | 0.77 | CDC7 (0.62) | ALDH1A1HSD17B10CDC7DBF4MAPT | |
| SCHEMBL3399807 | 0.76 | CDC7 (0.51) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL13071032 | 0.76 | ALDH1A1 (0.45) | DHODHALDH1A1HSD17B10CDC7DBF4 | |
| SCHEMBL3406836 | 0.76 | CDC7 (0.48) | ALDH1A1HSD17B10CDC7DBF4MAPT | |
| SCHEMBL1505433 | 0.76 | LMNA (0.48) | DHODHALDH1A1HSD17B10CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | NOTUM 362/4885DHODH 1245/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.